Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francis J Dumont

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Current Opinion in Investigational Drugs (London, England : 2000)|November 15, 2002
Overview: transplantation tolerance--challenges and opportunities for drug developmentFrancis J Dumont
Current Opinion in Investigational Drugs (London, England : 2000)|February 5, 2004
T-cell depletion for transplant tolerance induction: promises and hurdlesFrancis J Dumont
Current Opinion in Investigational Drugs (London, England : 2000)|June 19, 2004
ISAtx-247 (Isotechnika/Roche)Francis J Dumont
Current Opinion in Investigational Drugs (London, England : 2000)|November 30, 2005
Cytokines: the magic is still thereFrancis J Dumont
Current Opinion in Investigational Drugs (London, England : 2000)|May 26, 2005
Fontolizumab Protein Design LabsFrancis J Dumont
Expert Review of Anticancer Therapy|July 13, 2002
CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyondFrancis J Dumont
Current Opinion in Investigational Drugs (London, England : 2000)|July 2, 2002
IDEC-131. IDEC/EisaiFrancis J Dumont
Current Opinion in Molecular Therapeutics|July 22, 2004
Technology evaluation: abatacept, Bristol-Myers SquibbFrancis J Dumont
Idrugs : the Investigational Drugs Journal|March 18, 2005
Fingolimod. Mitsubishi Pharma/NovartisFrancis J Dumont
Current Cancer Drug Targets|July 27, 2012
Disrupting the mTOR signaling network as a potential strategy for the enhancement of cancer radiotherapyFrancis J Dumont, Pierre Bischoff
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Current Opinion in Investigational Drugs (London, England : 2000)|November 15, 2002
Overview: transplantation tolerance--challenges and opportunities for drug developmentFrancis J Dumont
Current Opinion in Investigational Drugs (London, England : 2000)|February 5, 2004
T-cell depletion for transplant tolerance induction: promises and hurdlesFrancis J Dumont
Current Opinion in Investigational Drugs (London, England : 2000)|June 19, 2004
ISAtx-247 (Isotechnika/Roche)Francis J Dumont
Current Opinion in Investigational Drugs (London, England : 2000)|November 30, 2005
Cytokines: the magic is still thereFrancis J Dumont
Current Opinion in Investigational Drugs (London, England : 2000)|May 26, 2005
Fontolizumab Protein Design LabsFrancis J Dumont
Expert Review of Anticancer Therapy|July 13, 2002
CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyondFrancis J Dumont
Current Opinion in Investigational Drugs (London, England : 2000)|July 2, 2002
IDEC-131. IDEC/EisaiFrancis J Dumont
Current Opinion in Molecular Therapeutics|July 22, 2004
Technology evaluation: abatacept, Bristol-Myers SquibbFrancis J Dumont
Idrugs : the Investigational Drugs Journal|March 18, 2005
Fingolimod. Mitsubishi Pharma/NovartisFrancis J Dumont
Current Cancer Drug Targets|July 27, 2012
Disrupting the mTOR signaling network as a potential strategy for the enhancement of cancer radiotherapyFrancis J Dumont, Pierre Bischoff
Pageof 2